Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
emptyimage
PP-PF-ONC-GB-0398 | February 2024

Oncology Homepage

Products
Stivarga® (regorafenib)
In mCRC
PP-STI-GB-0204, February 2024
Nexavar® (sorafenib) & Stivarga® (regorafenib)
In HCC
PP-NEX-GB-0211, February 2024
Xofigo®▼ (radium-223 dichloride)
In mCRPC
PP-XOF-GB-0460, February 2024
NUBEQA®▼ (darolutamide)
In nmCRPC and mHSPC
PP-NUB-GB-1317, February 2024
Resources
View more
mCRC Resources
STIVARGA® (regorafenib)
PP-STI-GB-0199, February 2024
NUBEQA®▼ (darolutamide) Resources
PP-NUB-GB-1312, February 2024
HCC Resources
Nexavar® (sorafenib) | Stivarga® (regorafenib)
PP-NEX-GB-0215, February 2024
Xofigo®▼ (radium-223 dichloride) Resources
PP-XOF-GB-0516, February 2024
Events & Webinars
View more
ASCO-GU 2023: ARASENS post-hoc analysis
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1297, February 2024
ASCO-GU 2023: The DEAR study in nmCRPC
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1296, February 2024
Ask the experts: Three key questions on mCRC
Stivarga® (regorafenib)
PP-STI-GB-0205, February 2024
BAUN 2022
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1314, February 2024
Podcasts
View more
Current treatment landscape and the future for treating mCRC
Stivarga® (regorafenib)
PP-STI-GB-0201, February 2024
Episode 3
The Practicalities of Treatment — Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0464, February 2024
Episode 1
Why treat with Xofigo®▼ (radium-223 dichloride)?
PP-XOF-GB-0462, February 2024
Episode 2
Optimising patient identification and referral — Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0463, February 2024
Register with BayerPRO

To access additional resources, personalise your experience and keep up to date via electronic communications from Bayer.

 

Areas of Interest
Cardiovascular
Women's Health
Nephrology
Oncology
Respiratory
Reporting adverse events and quality complaints

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc.

If you want to report an adverse event or quality complaint, reports can be directed to Tel: 0118 206 3500 or Email: pvuk@bayer.com. 

Further information is available on the "contact" tab at www.bayer.co.uk.

Register with BayerPRO

To access additional resources, personalise your experience and keep up to date via electronic communications from Bayer.

Register | Login

BayerPRO is developed and fully funded by Bayer plc.​ ​